Trends in paediatric inflammatory bowel disease‐attributable direct costs: a population‐based analysis

El-Matary, Wael; Nugent, Zoann; Witt, Julia; Bernstein, Çharles N.

doi:10.1111/apt.16358

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Manitoba study reported significantly increasing total direct healthcare costs (including the costs of outpatient care, hospitalizations, surgeries, and medication) among people with IBD, from $3,354 per person per year in 2005 to $7,801 in 2015 (costs in 2015 CAD) ( 1 ). The increase in costs has been even greater for paediatric IBD, increasing from $1811 per person per year in 2004 to $14,792 per person per year in 2017 (costs in 2020 CAD); the cost of caring for children without IBD did not change over the course of the study ( 9 ). The average direct costs among children in Ontario diagnosed at <17 years of age between 2013 and 2019 was $14,451 (SD: 14,665) in the first year following diagnosis ( 29 ).…”

Section: Estimating the Total Direct Costs Of Ibd In Canadamentioning

confidence: 98%

“…In these studies, hospitalization costs were averaged over all people with IBD, regardless of whether they were hospitalized. Costs of inpatient admissions for Manitoba children with IBD decreased from $365,252 in 2004 to $61,600 in 2017 ( P < 0.01); per-person hospitalization costs were not reported (costs in 2018 CAD) ( 9 ). The authors attributed this decrease in hospitalization costs to a reduction in IBD-related surgeries.…”

Section: Hospitalizationsmentioning

confidence: 99%

“…As IBD management has evolved, surgery rates have decreased ( Table 2 ) ( 1–4 , 9 , 10 , 13 ). However, these declining trends existed before the introduction of biologics, and their introduction into the market has not appreciably changed the rate at which surgeries are decreasing ( 4 ).…”

Section: Surgeriesmentioning

confidence: 99%

See 2 more Smart Citations

The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs

Kuenzig,

Coward,

Targownik

et al. 2023

Journal of the Canadian Association of Gastroenterology

Self Cite

View full text Add to dashboard Cite

Healthcare utilization among people living with inflammatory bowel disease (IBD) in Canada has shifted from inpatient management to outpatient management; fewer people with IBD are admitted to hospitals or undergo surgery, but outpatient visits have become more frequent. Although the frequency of emergency department (ED) visits among adults and seniors with IBD decreased, the frequency of ED visits among children with IBD increased. Additionally, there is variation in the utilization of IBD health services within and between provinces and across ethnocultural and sociodemographic groups. For example, First Nations individuals with IBD are more likely to be hospitalized than the general IBD population. South Asian children with Crohn’s disease are hospitalized more often than their Caucasian peers at diagnosis, but not during follow-up. Immigrants to Canada who develop IBD have higher health services utilization, but a lower risk of surgery compared to individuals born in Canada. The total direct healthcare costs of IBD, including the cost of hospitalizations, ED visits, outpatient visits, endoscopy, cross-sectional imaging, and medications are rising rapidly. The direct health system and medication costs of IBD in Canada are estimated to be $3.33 billion in 2023, potentially ranging from $2.19 billion to $4.47 billion. This is an increase from an estimated $1.28 billion in 2018, likely due to sharp increases in the use of biologic therapy over the past two decades. In 2017, 50% of total direct healthcare costs can be attributed to biologic therapies; the proportion of total direct healthcare costs attributed to biologic therapies today is likely even greater.

show abstract

Section: Estimating the Total Direct Costs Of Ibd In Canadamentioning

confidence: 98%

Section: Hospitalizationsmentioning

confidence: 99%

See 1 more Smart Citation

The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs

Kuenzig,

Coward,

Targownik

et al. 2023

Journal of the Canadian Association of Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

“…OOP costs are those paid by the patients or their caregivers in cash or credit for healthcare related expenses that are not covered by the public health or insurance systems, such as disease‐related travel and parking costs, and costs of over‐the‐counter medications (1,2). In children and young adults with IBD, we recently demonstrated that the median annual direct costs per person were $1811 (Canadian dollars) in 2004 and significantly increased to $14,792 in 2017 (3). A recent report from Crohn’s & Colitis Canada showed that the direct cost of caring for people living with IBD in Canada in 2018 was estimated to be close to $1.28 billion and the total indirect and OOP costs were estimated to be $1.29 billion (4,5).…”

mentioning

confidence: 99%

Indirect and Out-of-Pocket Disease-associated Costs in Pediatric Inflammatory Bowel Disease: A Cross-sectional Analysis

El-Matary

Witt

Bernstein

et al. 2022

Journal of Pediatric Gastroenterology &Amp; Nutrition

Self Cite

View full text Add to dashboard Cite

Objectives: Data on pediatric inflammatory bowel disease (IBD)-associated indirect and out-of-pocket (OOP) costs are limited. We aimed to estimate indirect (lost work hours and productivity) and OOP pediatric IBD-associated costs in Canada. Methods: In a nation-wide cross-sectional analysis, caregivers of children with IBD were invited to complete a questionnaire on lost work hours and OOP costs related to IBD in the 4 weeks prior to the survey. Participants were reinvited to periodically answer the same questionnaire every 3-9 months for 2 years. Lost productivity was calculated using the Human Capital method. Costs were reported in 2018 inflation-adjusted Canadian dollars. Predictors of high cost users (top 25%) were examined using binary logistic regression. Results: Consecutive 243 (82 incident cases) of 262 (92.7%) approached participants completed the first survey with a total of 450 surveys longitudinally completed over 2 years. The median annual indirect cost per patient was $5966

show abstract

Inflammatory bowel disease substantial burden among children in Manitoba, Canada

2021

PharmacoEcon Outcomes News

View full text Add to dashboard Cite

The direct healthcare costs among children with inflammatory bowel disease (IBD) have increased significantly over the last two decades in the Province of Manitoba, Canada, mainly driven by medications costs.These are the main findings of a population-based study conducted by researchers from the University of Manitoba, Canada, to examine the direct IBD-related costs for the period between 1995 and 2017 in children and young adults diagnosed with IBD before the age of 18 years. The study used data from an IBD registry dataset as well as claims data. Hospital costs, and consequently total direct costs, were calculated for the period from 2004 to 2017.The analysis, which included data from 733 children and young adults diagnosed with IBD, showed a significant increase in IBD-attributable total direct costs, from $Can670 783 in 2004 to $Can2 069 708 in 2017 (year 2018 values). Total direct costs were significantly higher in children and young adults with IBD compared to those of a matched control group without IBD. The median annual direct costs per person with IBD were $Can1811 in 2004, with a significant increase to $Can14 792 in 2017, while direct costs for healthcare services remained stable in the control group. In children and young adults with IBD, the main driver of the direct costs in the year of IBD diagnosis was physician's billings. After the first year, the main driver of costs was medication costs, mainly tumour necrosis-factor antagonists (anti-TNFs). The costs of inpatient care declined from 2004 to 2017, but overall total direct costs increased over the period due to a significant increase in medication costs. IBD-attributable direct costs were higher in persons with CD compared to those of persons with UC.

show abstract

Trends in paediatric inflammatory bowel disease‐attributable direct costs: a population‐based analysis

Cited by 7 publications

References 24 publications

The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs

The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs

Indirect and Out-of-Pocket Disease-associated Costs in Pediatric Inflammatory Bowel Disease: A Cross-sectional Analysis

Inflammatory bowel disease substantial burden among children in Manitoba, Canada

Contact Info

Product

Resources

About